<DOC>
	<DOCNO>NCT00348725</DOCNO>
	<brief_summary>The primary objective ass acceptability 4-week treatment 4 new fixed-dose combination fenofibrate metformin , patient type 2 diabetes dyslipidemia .</brief_summary>
	<brief_title>Acceptability Fixed Combination Fenofibrate Metformin</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Glucose Metabolism Disorders</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Patients type 2 diabetes mellitus dyslipidemia . Type 1 diabetes , uncontrolled type 2 diabetes , HbA1c â‰¥ 10 % Fasting plasma glucose &gt; 300 mg/dL Triglycerides &gt; 500 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Treatment Dyslipidemia Type 2 Diabetes Mellitus</keyword>
</DOC>